Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: An analysis from the DECLARE-TIMI 58 randomised trial - Mosenzon, O; Wiviott, S D; Cahn, A (Lancet Diabetes Endocrinol, 2019)
et al.